# InduPro Therapeutics

Source: https://onco.cc/companies/indupro-therapeutics/  
OnCo record `indupro-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

InduPro Therapeutics maps which proteins sit side by side on the surface of cancer cells and designs two-armed antibody-drug conjugates that bind such a pair. Its first medicine, for lung and other squamous cancers, entered a phase 1 trial in 2026.

## Summary

InduPro Therapeutics, formed in 2022 with offices in Seattle and Cambridge, Massachusetts, uses a proximity-guided discovery platform to find Tumour Associated Proximity Antigens (TAPAs), proteins that sit next to a known target on cancer cells, and builds bispecific antibody-drug conjugates against the pair. Its lead IDP-001 is a bispecific ADC against EGFR and TAPA-E1; on 12 August 2026 the company reported the first patient dosed in a phase 1 study (NCT07602842) in advanced or metastatic squamous or non-squamous non-small cell lung cancer and other squamous solid tumours. Further programmes listed include IDP-012 (EGFR x TAPA-E1 with a topoisomerase 1 inhibitor payload), IDP-004 (MET x TAPA-M1) and PD-1 bispecifics for immuno-oncology and autoimmunity. Financing comprises an USD 85 million Series A in June 2024 co-led by The Column Group and Vida Ventures and a USD 77 million Series B in August 2026 led by The Column Group, with Sanofi and Eli Lilly among new investors; Lilly also signed an oncology collaboration in January 2026.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: InduPro
- HQ: Seattle, WA
- Type: biotech
- Website: https://www.induprotx.com/

## Notes

- TAPA-E1 and TAPA-M1 are the company's own names for undisclosed partner antigens. The Endpoints figure of up to USD 950 million for the Lilly collaboration was seen only as a headline and is not stated here as a fact.

## Sources

- Official website: https://www.induprotx.com/
- USD 85 million Series A, June 2024: https://www.biospace.com/indupro-announces-85-million-series-a-financing-appoints-prakash-raman-ph-d-as-ceo-to-advance-next-generation-proximity-based-protein-therapeutics-for-the-treatment-of-cancer-and-autoimmune-diseases
- USD 77 million Series B and first patient dosed with IDP-001, August 2026: https://www.induprotx.com/news/indupro-closes-77-million-series-b-financing-and-doses-first-patient-in-phase-1-study-of-lead-oncology-program-idp-001/
- Pipeline: https://www.induprotx.com/pipeline/

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Bispecific ADC](https://onco.cc/technologies/bispecific-adc/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/)
- targets: [EGFR](https://onco.cc/targets/egfr/), [MET](https://onco.cc/targets/met/)
- trials: [A Study of IDP-001 in Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct07602842/)
- companies: [Vida Ventures](https://onco.cc/companies/vida-ventures/)

---
JSON: https://onco.cc/api/v1/entities/indupro-therapeutics.json